Celcuity (CELC) Projected to Announce Earnings on Thursday

Celcuity (NASDAQ:CELC) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($1.51) per share and revenue of $1.60 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, analysts expect Celcuity to post ($4.98) EPS for the current fiscal year and ($2.53) EPS for the next fiscal year.

Celcuity Stock Up 4.2%

CELC stock traded up $2.79 during midday trading on Tuesday, reaching $69.86. 253,205 shares of the company were exchanged, compared to its average volume of 1,144,075. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. Celcuity has a 1-year low of $53.54 and a 1-year high of $151.02. The stock’s 50-day simple moving average is $77.14 and its 200 day simple moving average is $100.19. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -16.27 and a beta of 0.10.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CELC. Stifel Nicolaus reduced their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Wall Street Zen lowered Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Monday, October 19th. JPMorgan Chase & Co. initiated coverage on Celcuity in a research report on Thursday, September 17th. They issued an “overweight” rating and a $157.00 price target on the stock. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $177.00 price objective on shares of Celcuity in a research note on Monday, August 17th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $152.57.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.